arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Inmune Bio, Inc.

INMB
$2.08 ▲ +0.18 (+9.19%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
35 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
13
Health
Poor
Bearish
auto_awesome

Analytical Summary

Inmune Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $55.3M
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -23.4%
FCF / Share $-0.13
Trailing P/E
Price / Book 2.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-5.41M
↑ +44.5%
FCF / Share Free cash flow per share
$-0.13
↑ +57.8%
Long-Term Debt Long-term obligations
$15.00M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
3
Cash Quality
41

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters